XenoPort (XNPT) says its restless leg drug Horizant is sold out, and in this case, that's a bad...

|By:, SA News Editor

XenoPort (XNPT) says its restless leg drug Horizant is sold out, and in this case, that's a bad thing. GlaxoSmithKline (GSK), which has commercialization rights to the treatment through the end of this month, reports manufacturing delays have led to a stockout of Horizant. XNPT says it is "evaluating the impact, if any, this will have" on financial expectations. Shares -2.48% premarket.